Rapamycin levels in tumor homogenates from indicated treatment groups were measured 24 hours (A, C) and 48 hours (B, D) after the final dose of rapamycin. Panels C and D are enlarged versions of the boxed-in data in panels A and B respectively.<p><b>Copyright information:</b></p><p>Taken from "Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model"</p><p>http://www.biomedcentral.com/1471-5945/8/1</p><p>BMC Dermatology 2008;8():1-1.</p><p>Published online 28 Jan 2008</p><p>PMCID:PMC2266897.</p><p></p